1-20 of 46
Cynthia X. Ma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB–Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer

Available to Purchase
Shuyan Zhou, Yi Zhang, Julie Belmar, Chunyan Hou, Yaqin Zhang, Changmin Peng, Yunxiao Meng, Zhuqing Li, Muhammad Jameel Mughal, Yanjun Gao, Edward Seto, Min Shen, Matthew D. Hall, Junfeng Ma, Cynthia X. Ma, Shunqiang Li, Wenge Zhu
Journal: Cancer Research
Cancer Res (2025) 85 (9): 1708–1724.
https://doi.org/10.1158/0008-5472.CAN-24-2492
Published: 02 May 2025
View articletitled, Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB–Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer
Open the PDF for Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB–Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract CT071: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)

Free
Andrew A. Davis, Haeseong Park, Ecaterina E. Dumbrava, Nataliya V. Uboha, Aparna Kalyan, Farshid Dayyani, Mili Arora, Miguel A. Villalona-Calero, Haider S. Mahdi, Reema A. Patel, Floor Backes, Jessica Porzel, Whitney L. Hensing, Cheryl Pickett, Cynthia X. Ma, Ron Bose
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT071.
https://doi.org/10.1158/1538-7445.AM2025-CT071
Published: 25 April 2025
View articletitled, Abstract CT071: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)
Journal Articles

Abstract 2809: Targeting the LINC00355-MENIN interaction with CDK4/6 inhibitors to reduce proliferation in late relapse breast cancer

Free
Richa Mishra, Brianna Duhart, Dhanusha Duraiyan, Prasanth Thunuguntla, Kyla Gelev, Debbie C. Crans, Cynthia X. Ma, Jessica Silva-Fisher
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 2809.
https://doi.org/10.1158/1538-7445.AM2025-2809
Published: 21 April 2025
View articletitled, Abstract 2809: Targeting the LINC00355-MENIN interaction with CDK4/6 inhibitors to reduce proliferation in late relapse breast cancer
Journal Articles

Abstract 5339: Single cell analysis enables tracking the evolution of resistance to CDK4/6 inhibitors in ER+ breast cancer

Free
Yuki Matsunaga, Emma Aleksandrovic, Hima M. Patel, Dhivya R. Sudhan, Khushi Ahuja, Dan Ye, Chang-Ching A. Lin, Lei Guo, Cynthia X. Ma, Jeon Lee, Siyuan Zhang, Carlos L. Arteaga, Ariella B. Hanker
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 5339.
https://doi.org/10.1158/1538-7445.AM2025-5339
Published: 21 April 2025
View articletitled, Abstract 5339: Single cell analysis enables tracking the evolution of resistance to CDK4/6 inhibitors in ER+ breast cancer
Journal Articles

Abstract CT159: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)

Free
Andrew A. Davis, Ecaterina E. Dumbrava, Aparna Kalyan, Nataliya V. Uboha, Haider S. Mahdi, Reema A. Patel, Farshid Dayyani, Jessica Porzel, Whitney L. Hensing, Cynthia X. Ma, Ron Bose, Haeseong Park
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT159.
https://doi.org/10.1158/1538-7445.AM2024-CT159
Published: 05 April 2024
View articletitled, Abstract CT159: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)
Journal Articles

Abstract 977: Germline BRCA1/2 mutations detected by circulating tumor DNA testing in breast cancer patients: A retrospective mutiinstitutional analysis

Free
Letizia Pontolillo, Carolina Reduzzi, Andrew A. Davis, Arielle J. Medford, Annika Putur, Lorenzo Gerratana, Katherine Clifton, Whitney L. Hensing, Marko Velimirovic, Surbhi Warrior, Mara S. Serafini, Eleonora Nicolò, Laura Munoz-Arcos, Jeannine Donahue, Charles S. Dai, Jennifer C. Keenan, Amir Behdad, William J. Gradishar, Diana Giannarelli, Emilio Bria, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 977.
https://doi.org/10.1158/1538-7445.AM2024-977
Published: 22 March 2024
View articletitled, Abstract 977: Germline BRCA1/2 mutations detected by circulating tumor DNA testing in breast cancer patients: A retrospective mutiinstitutional analysis
Journal Articles

Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study

Free
Mara Serena Serafini, Carolina Reduzzi, Lorenzo Gerratana, Rinath Jeselsohn, Reshma L. Mahtani, Cynthia X. Ma, Angela DeMichele, Jane Lowe Meisel, Kathy D. Miller, Yara Abdou, Elizabeth C. Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Harold J. Burstein, Sara M. Tolaney, Michelle K. DeMeo, Yuan Liu, Eric Gauthier, Yue Ren, Meredith M. Regan, Huiping Liu, Erica L. Mayer, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3707.
https://doi.org/10.1158/1538-7445.AM2024-3707
Published: 22 March 2024
View articletitled, Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study
Journal Articles

Abstract 2420: Evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker utilizing a tissue-free epigenomic assay in early-stage triple negative breast cancer (TNBC)

Free
Foluso O. Ademuyiwa, Cynthia X. Ma, Katherine Weilbaecher, Rama Suresh, Lindsay Peterson, Ron Bose, Nusayba Bagegni, Caron E. Rigden, Ashley Frith, Katherine Clifton, Andrew Davis, Derek Dustin, Mingyang Cai
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2420.
https://doi.org/10.1158/1538-7445.AM2024-2420
Published: 22 March 2024
View articletitled, Abstract 2420: Evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker utilizing a tissue-free epigenomic assay in early-stage triple negative breast cancer (TNBC)
Journal Articles

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

Open Access
Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal, Yuefan Wang, Andrew T. Shinkle, Michael C. Wendl, Tina M. Primeau, Yanyan Zhao, Alanna Gould, Hua Sun, Jacqueline L. Mudd, Jeremy Hoog, R. Jay Mashl, Matthew A. Wyczalkowski, Chia-Kuei Mo, Ruiyang Liu, John M. Herndon, Sherri R. Davies, Di Liu, Xi Ding, Yvonne A. Evrard, Bryan E. Welm, David Lum, Mei Yee Koh, Alana L. Welm, Jeffrey H. Chuang, Jeffrey A. Moscow, Funda Meric-Bernstam, Ramaswamy Govindan, Shunqiang Li, James Hsieh, Ryan C. Fields, Kian-Huat Lim, Cynthia X. Ma, Hui Zhang, Li Ding, Feng Chen
Journal: Cancer Research
Cancer Res (2023) 83 (24): 4161–4178.
https://doi.org/10.1158/0008-5472.CAN-23-0604
Published: 15 December 2023
View articletitled, Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
Open the PDF for Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial

Free
Matthew J. Ellis, Meenakshi Anurag, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard Gibbs, Souzan Sanati, Kiran Vij, Mark Watson, Travis Dockter, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erica Crouch, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, A. Marilyn Leitch, Gary W. Unzeitig, Eric Winer, Anna Weiss, Kelly Hunt, Ann H. Partridge, Charles M. Perou, Vera Suman, Cynthia X. Ma, Lisa A. Carey
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT026.
https://doi.org/10.1158/1538-7445.AM2022-CT026
Published: 15 June 2022
View articletitled, Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial
Journal Articles

Abstract PD9-03: Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)

Free
Cynthia X Ma, Meenakshi Anurag, Travis Dockter, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard Gibbs, Souzan Sanati, Kiran Vij, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J Hieken, Yang Wang, A. Marilyn Leitch, Gary W Unzeitig, Anna Weiss, Eric P Winer, Kelly Hunt, Ann H Partridge, Lisa A Carey, Charles M Perou, Matthew J Ellis, Vera Suman
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD9-03.
https://doi.org/10.1158/1538-7445.SABCS21-PD9-03
Published: 15 February 2022
View articletitled, Abstract PD9-03: Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)
Journal Articles

Abstract PD6-06: Comprehensive characterization of neurotransmitters and neuronal signaling gene alterations in invasive breast cancers

Free
Irene Kang, Krutika Deshpande, Sarah Persing, Jun Yin, Joanne Xiu, Wolfgang Michael Korn, Jia Zeng, Evanthia T Roussos-Torres, Janice Lu, Darcy Spicer, Stephen F Sener, Antoinette R Tan, Ashley Sumrall, David SB Hoon, Cynthia X Ma, Carey K Anders, Heather L McArthur, Reva Basho, Heinz-Josef Lenz, Josh Neman
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD6-06.
https://doi.org/10.1158/1538-7445.SABCS21-PD6-06
Published: 15 February 2022
View articletitled, Abstract PD6-06: Comprehensive characterization of neurotransmitters and neuronal signaling gene alterations in invasive breast cancers
Journal Articles

Abstract P3-09-04: Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations

Free
Jing Xi, Kathleen Harnden, Jingqin Luo, Greg S. Call, Elizabeth Mauer, Karyn Ronski, Cynthia X. Ma, Neil Vasan
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P3-09-04.
https://doi.org/10.1158/1538-7445.SABCS21-P3-09-04
Published: 15 February 2022
View articletitled, Abstract P3-09-04: Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations
Journal Articles

Abstract PD14-04: Circulating tumor DNA characterization of invasive lobular carcinoma in patients with metastatic breast cancer

Free
Andrew A Davis, Lorenzo Gerratana, Katherine Clifton, Marko Velimirovic, Whitney L Hensing, Ami N Shah, Paolo D’Amico, Carolina Reduzzi, Qiang Zhang, Charles S Dai, Elyssa N Denault, Nusayba A Bagegni, Mateusz Opyrchal, Foluso O Ademuyiwa, Ron Bose, William J Gradishar, Amir Behdad, Cynthia X Ma, Aditya Bardia, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD14-04.
https://doi.org/10.1158/1538-7445.SABCS21-PD14-04
Published: 15 February 2022
View articletitled, Abstract PD14-04: Circulating tumor DNA characterization of invasive lobular carcinoma in patients with metastatic breast cancer
Journal Articles

Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC)

Free
Marko Velimirovic, Lorenzo Gerratana, Andrew A Davis, Whitney L Hensing, Katherine Clifton, Ami N Shah, Paolo D'Amico, Charles S Dai, Elyssa N Denault, Cynthia X Ma, Seth A Wander, Dejan Juric, Massimo Cristofanilli, Bruce A Chabner, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-07-02.
https://doi.org/10.1158/1538-7445.SABCS21-P2-07-02
Published: 15 February 2022
View articletitled, Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC)
Journal Articles

Abstract PD6-08: Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS)

Free
Lorenzo Gerratana, Andrew A Davis, Marko Velimirovic, Katherine Clifton, Whitney L Hensing, Ami N Shah, Charles S Dai, Carolina Reduzzi, Paolo D’Amico, Qiang Zhang, Firas Wehbe, Seth Wander, William J Gradishar, Amir Behdad, Fabio Puglisi, Cynthia X Ma, Aditya Bardia, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD6-08.
https://doi.org/10.1158/1538-7445.SABCS21-PD6-08
Published: 15 February 2022
View articletitled, Abstract PD6-08: Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS)
Journal Articles

Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy

Free
François-Clément Bidard, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen KL Chia, Wolfgang Janni, Cynthia X Ma, Erica L Mayer, Yeon Hee Park, Steven Fox, Xiaochun Liu, Andrew Walding, Cynthia Huang Bartlett, Nick C Turner
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-11-05.
https://doi.org/10.1158/1538-7445.SABCS21-OT2-11-05
Published: 15 February 2022
View articletitled, Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy
Journal Articles

Abstract P2-01-01: Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC)

Free
Whitney L Hensing, Lorenzo Gerratana, Katherine Clifton, Marko Velimirovic, Ami Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S Dai, Nusayba A Bagegni, Mateusz Opyrchal, Foluso O Ademuyiwa, Bose Ron, Amir Behdad, Cynthia X Ma, Aditya Bardia, Massimo Cristofanilli, Andrew A Davis
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-01-01.
https://doi.org/10.1158/1538-7445.SABCS21-P2-01-01
Published: 15 February 2022
View articletitled, Abstract P2-01-01: Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC)
Journal Articles

Abstract P2-13-01: Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+ HER2+ breast cancer (PALTAN)

Free
Foluso O Ademuyiwa, Donald Northfelt, Tracey O'Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S Hagemann, Cynthia X Ma
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-01.
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-01
Published: 15 February 2022
View articletitled, Abstract P2-13-01: Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+ HER2+ breast cancer (PALTAN)
Journal Articles

Abstract OT2-07-01: The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer

Free
Cynthia X. Ma, Robert Maganini, Pat Whitworth, Jennifer A. Crozier, Joyce O'Shaughnessy, Sami Diab, Beth-Ann Lesnikoski, June Lee, Nina D'Abreo, Blanche H. Mavromatis, Pond Kelemen, Darina Pronin, Hiwot Abebe, Michelle L. Bolner, Christine Finn, Lisa Blumencranz, William Audeh, FLEX Investigators Group
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-07-01.
https://doi.org/10.1158/1538-7445.SABCS21-OT2-07-01
Published: 15 February 2022
View articletitled, Abstract OT2-07-01: The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer